We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative vaccines for a healthier world
Advancing groundbreaking vaccines through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.
Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.
ES2B-C001: Advancing HER2 Cancer Immunotherapy
At ExpreS2ion Biotech, we are transforming HER2 cancer immunotherapy with ES2B-C001, a novel vaccine built on our proprietary ExpreS2 platform for the efficient production of high-quality HER2 antigens. By combining these antigens with a virus-like particle (VLP) delivery system, ES2B-C001 effectively engages the immune system to generate a broad and durable antibody response. Targeting all four extracellular domains of the HER2 receptor, it offers superior tumour inhibition and resistance prevention compared to traditional monoclonal antibody therapies.
Watch the video below to learn more about this breakthrough approach.
Latest news
Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases
Hørsholm, Denmark, 10 November 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing innovative vaccine candidates targeting infectious diseases and cancer, today announces continued clinical progress across several University of Oxford malaria vaccine programs, which apply the ExpreS2 platform. The advancement of these studies continues to support evidence…
Read moreExpreS2ion Hereby Changes Certified Advisor to Redeye
Hørsholm, Denmark, 7 November 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) today announces it has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on February 1, 2026. Until then, Svensk Kapitalmarknadsgranskning AB will continue as Certified Adviser to…
Read moreExpreS2ion to Participate in Key Investor and Industry Events in November 2025
Hørsholm, Denmark, 3 November 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in November 2025: BIO-Europe, the 2025 Interim Report (Q3) Presentation and the BioStock Life Science Summit.
Read more